Letter to Industry Canada re: Addition of oseltamivir phosphate to Schedule 1 to the Patent Act

« On July 1, 2006 the Departments of Industry and Health published, in Part I of the Canada Gazette, the proposed text of an order to amend Schedule 1 to the Patent Act to add « oseltamivir phosphate », in both capsule form as well as in powder for oral suspension, to the list of patented pharmaceutical products eligible to be exported under compulsory license. The Canadian HIV/AIDS Legal Network wishes to register its support for the proposed amendment, and to encourage the Governor in Council to make the proposed order without further delay… »